Figure 6. Human CD83-targeted CAR T cells significantly reduce CD4⁺ and CD83⁺ T cells while increasing the Treg/activated Tconv ratio in vivo.

NSG mice received 25 × 10⁶ human PBMCs plus 1 × 10⁶ CD83 CAR or mock-transduced T cells as described. Mice were humanely euthanized on day +21 and the spleens were harvested. (A) Representative contour plots show the amount of EGFP⁺ CD83 CAR T cells in the inoculated mice at day +21, compared with mice that received mock-transduced T cells. (B) Representative contour plots show the frequency of human CD4⁺ T cells in the recipient spleens. Graphs show the absolute numbers (mean ± SEM) of (C) CD4⁺ and (D) CD4⁺ CD83⁺ T cells in the mouse spleens at day +21. (E) Contour plots depict the percentage of CD4⁺, CD127^–, CD25⁺, Foxp3⁺ Tregs in the mouse spleens at day +21. Graphs show the amount (mean ± SEM) of (F) Tregs and the (G) Treg/activated Tconv ratio at day +21 in the recipient mice. (H) Contour plots depict the frequency of CD4⁺ IFN-γ⁺ Th1 cells and CD4⁺ IL-4⁺ Th2 cells in the mouse spleens at day +21. Graphs demonstrate the absolute numbers (mean ± SEM) of (I) Th1 and (J) Th2 cells in the recipient spleens. Pooled data from 2 independent experiments, up to 6 mice per experimental arm. ANOVA (C, D, F, G, I, and J). *P < 0.05, **P = 0.001–0.01.